The London Company Large Cap portfolio declined 0.2% during the second quarter (-0.4% net) vs. a 3.8% increase in the Russell ...

The London Company Large Cap portfolio declined 0.2% during the second quarter (-0.4% net) vs. 11.1% increase in the Russell ...

Achieves Key Guidance Metrics Reaffirms 2024/2025 Two-Year Adjusted Free Cash Flow guidance TYSONS, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- TEGNA Inc. (NYSE: TGNA) today announced financial results ...

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only ...

Phase 2 topline data from Avail trial expected in Q3 2025. Topline results from the Phase 2 Avail trial of canvuparatide, a potential long-acting, once-weekly parathyroid hormone (PTH) peptide prodrug ...